← All trials
NCT04810728
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2020
- Primary completion
- Dec 4, 2020
- Completion date
- Jan 30, 2021
- First posted
- Mar 23, 2021
- Last posted
- Apr 20, 2021
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baiturrahmah UniversityLead sponsor
- Baiturrahmah UniversityReponsible party - principal investigator
- Baiturrahmah UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.